loader2
Login OPEN ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Risk reward still favours PSU bank valuations

30 Dec 2022|
8 min read |
by ICICI Securities Team

A stellar run up by PSU banks had all eyes glued towards them. We tried to analyse the factors leading to the rally and what is in store ahead. Bank Nifty gained ~28% whereas PSU banks were up 74% in the last six months (as of December 21, 2022). Post the phase of significantly higher GNPA, treasury MTM losses, lower capital & sub-par growth, there has been a turnaround with comfort on asset quality; reversal of treasury losses, credit growth pick-up and just adequate capital position for most of them. Despite the decent rally, valuation still look reasonable for PSU banks.

PSU bank trends over last few quarters/years:

GNPA, NNPA ratio decline picks up pace in last five quarters

The asset quality trend continued to improve led by healthy recoveries and steady incremental slippages. Absolute GNPA and NNPA declined 16% and 30% YoY, respectively, in Q2FY23 after a similar cut in Q3FY21. GNPA, NNPA ratio for PSU banks declined from 9.4%, 2.4% in Q3FY21 to 6.6%, 1.8% in Q2FY23, respectively. Management comments, revival in the economy suggest an improvement in asset quality and lower credit cost ahead with PCR currently around 75%.

Credit growth back to 20% for PSU banks from low single digits

Loans recorded growth of 20.4% YoY, 4.8% QoQ to Rs 120.4 lakh crore. However, PSU banks saw growth surging to 20.1% in Q2FY23 (including international) from ~3% in Q1FY22. Business momentum is healthy, attributable to robust demand in the retail & MSME segment. Corporate credit grew for most banks including PSU banks. Banking sectoral data (October 2022) shows the retail segment was up 20.2% YoY and agri credit jumped 13.6% YoY. Large corporate credit, which had been a drag on overall banking credit growth, has started to enter the positive territory in the past few quarters. Management commentaries and data indicate a revival in utilisation of working capital (WC) limits. Thus, we believe bank credit growth should continue to remain at 15-16%with PSU banks at 12-15%.

G-sec yields moderating, expect stabilisation

Treasury losses amid a run up in yields impacted the improvement in operational performance in Q1FY23. However, the recent decline in yields from 7.5% to 7.3% is expected to reverse these losses, which no longer seems an overhang for PSU banks.

Margins, PAT, return ratios going northwards

PSU banks reported 20% YoY and 13.6% QoQ growth in NII, highest in last eight quarters. Faster transmission of rate hikes on assets compared to liabilities and healthy proportion of low cost deposits led to strong sequential rise in margins (10- 40 bps QoQ). Management commentary suggests margins will remain steady at the current level in H2FY23. Led by a strong topline and lower credit cost, net profit of PSBs grew 19% YoY and 70% QoQ at Rs 26,021 crore for Q2FY23 depicting improving earnings. Hence, with expected sustainability of earnings growth, return ratios are improving. RoA has reached 0.6-0.8% in Q2FY23 similar to FY14-15 levels. We expect further improvement in RoA though RoE may take longer to surge, except for SBI, BoB, Indian Bank and Canara Bank where >11% RoE is reached.

Valuations still reasonable

Going ahead, the RoA for large PSU banks is seen inching towards 0.8-1% gradually. With a recovery in growth and stable asset quality, PSU banks are set for a further re-rating. Large PSU banks (SBI, BoB, Canara Bank) are trading at ~0.8-1x P/BV, which paves the way for a further re-rating as peak valuations remain at ~1.2-1.5x in FY12-14. Mid-sized and small banks, currently trading at 0.5-0.7x P/BV, touched ~1x then. We remain positive on PSU banks, with upsides expected to continue in the medium term horizon.

Source: ICICIdirect Research

Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. I-Sec is a SEBI registered with SEBI as a Research Analyst vide registration no. INH000000990. Name of the Compliance officer (broking): Ms. Mamta Shetty, Contact number: 022-40701022, E-mail address: complianceofficer@icicisecurities.com. Investments in securities markets are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest.  I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The non-broking products / services like Research, etc. are not exchange traded products / services and all disputes with respect to such activities would not have access to Exchange investor redressal or Arbitration mechanism. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

Disclaimer: ICICI Securities Ltd.( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Centre, H. T. Parekh Marg, Churchgate, Mumbai - 400020, India, Tel No : 022 - 2288 2460, 022 - 2288 2470.  The contents herein above shall not be considered as an invitation or persuasion to trade or invest.  Investments in securities market are subject to market risks, read all the related documents carefully before investing. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents are solely for informational and educational purpose.

Share
instagram facebook twitter linkedin mail whatsApp
Did you enjoy this article?

Recent Articles

View all

Repo Rate Hike Explained: Impact on Loans, Deposits, Bonds and Stock Market

13 Oct 2026

The Reserve Bank of India (RBI) held its 63rd Monetary Policy Committee (MPC) meeting from October 5 to 7, 2026. It raised the policy repo rate by 25 basis points. The stance was also changed from ‘neutral’ to ‘calibrated tightening’. India’s economy continued to show strong momentum, with real Gross Domestic Product (GDP) growing by 7.8% in Q1 FY2026-27. While inflation rose to 4.8% in August, the overall economic outlook remained positive. However, rise in crude oil prices amid renewed tensions in West Asia added to global uncertainties. This made it imperative for the RBI to strike a balance between the economic growth and price stability....

Jio Platforms IPO Review: Reasons for Launching an IPO & Industry Details

09 Oct 2026

Jio Platforms is the company behind Reliance Jio's mobile network, home broadband and a growing line-up of AI-powered products. The company filed its Draft Red Herring Prospectus (DRHP) with SEBI on June 19, 2026, and Red Herring Prospectus (RHP) on October 14, 2026. The Jio Platforms IPO opens on October 21, 2026 and closes on October 23, 2026. The RHP gives details about how the Jio Platforms IPO is structured, who currently owns the company, and where the raised money will be used. This article analyses RHP and says about how the issue is structured, how it is divided among investors, who is managing it, who owns the company today, the numbers behind the business and the market it operates in. It is for information only and not an investment advice....

Natco Pharma Ltd. Rights Issue: Price, Record Date, Entitlement Ratio And Key Details

09 Oct 2026

The Natco Pharma Ltd. rights issue is proposed at ₹750 per share, with eligible shareholders entitled to two rights equity shares for every 21 fully paid-up equity shares held on the record date. The issue is scheduled to open on October 12, 2026, and close on October 22, 2026. The pharmaceutical company plans to raise up to ₹1,279.35 crore through the issue, subject to full subscription and the finalisation of the basis of allotment....

Download
ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere

Download
ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere